Brilacidin is under clinical development by Innovation Pharmaceuticals and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Brilacidin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Brilacidin overview

Brilacidin (PMX-30063) is under development for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Staphylococcus aureus, including MRSA and MSSA, encephalitic alphaviruses, including venezuelan equine encephalitis virus (VEEV), eastern equine encephalitis virus (EEEV), and sindbis virus (SINV), chemotherapy induced oral mucositis in patients with head and neck cancer who have received chemoradiation, ulcerative proctosigmoiditis, monkeypox, ulcerative proctitis, hidradenitis suppurativa, acne and atopic dermatitis, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and COVID-19 associated cytokine storm and inflammatory bowel disease. It is administered through intravenous route, rectal route, topical, ophthalmic, auricular as well as orally. Brilacidin is a defensin mimetic compound which works as a bacterial cell membrane disruptor. The drug candidate is developed based on CDDT (computational drug design) technology. It was also under development for bacterial keratitis, lung infections, bacterial conjunctivitis, otitis media, vancomycin-resistant Enterococcus infections, diabetic foot wounds, ulcers caused by infections, bone and joint infections.

Innovation Pharmaceuticals overview

Innovation Pharmaceuticals, formerly Cellceutix, is a biopharmaceutical company that discovers and advances medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company provides pipeline products such as kevetrin for the treatment of advanced solid tumors and acute myelogenous leukemia, among others. Innovation Pharmaceuticals offers pipeline products such as Brilacidin for the treatment of oral mucositis and skin infections; and Prurisol for the treatment of psoriasis. It works in collaboration with various research institutions across the US and other European countries. Innovation Pharmaceuticals is headquartered in Beverly, Massachusetts, the US.

For a complete picture of Brilacidin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.